Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pharmacia acquires Sensus; Somavert under review at the FDA

March 8, 2001

Neose Technologies and Novazyme restructure enzyme replacement therapy agreement

March 8, 2001

New inhibitors of MTP and their use in lipid disorders, diabetes, obesity, etc.

March 7, 2001

Repligen reports positive phase I results of uridine in mitochondrial disease; phase II planned

March 7, 2001

FDA approves multidose formulation of Serono's Gonal-F for ovarian stimulation

March 7, 2001

Peptide GLP-1 and/or exendin-4 agonists identified by Danish pharmaceutical company

March 6, 2001

Results from two phase II trials with INS-1 in PCOS and dyslipidemia

March 6, 2001

New GH secretagogues in development at Merck

March 5, 2001

CPMP issues positive opinion for new NeoRecormon indication

March 5, 2001

First clinical study of acyline, a potent and long-acting GnRH antagonist

March 5, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...